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intracranial hemorrhage in patients with head injuries
Scott M Alter  ,1,2,3 Benjamin A Mazer  ,1 Joshua J Solano  ,1,2,3
Richard D Shih  ,1,2 Mary J Hughes  ,4 Lisa M Clayton  ,1,2,3
Spencer W Greaves  ,1 Nhat Q Trinh  ,5 Patrick G Hughes  1,2,3
ABSTRACT
Background Antiplatelet agents are increasingly used
in cardiovascular treatment. Limited research has been
performed into risks of acute and delayed traumatic
intracranial hemorrhage (ICH) in these patients who
sustain head injuries. Our goal was to assess the overall
odds and identify factors associated with ICH in patients
on antiplatelet therapy.
Methods A retrospective observational study was
conducted at two level I trauma centers. Adult patients
with head injuries on antiplatelet agents were enrolled
from the hospitals’ trauma registries. Acute ICH was
diagnosed by head CT. Observation and repeat CT to
evaluate for delayed ICH was performed at clinicians’
discretion. Patients were stratified by antiplatelet type
and analyzed by ICH outcome.
Results Of 327 patients on antiplatelets who
presented with blunt head trauma, 133 (40.7%) had
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acute ICH. Three (0.9%) had delayed ICH on repeat CT,
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were asymptomatic and did not require neurosurgical
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intervention. One with delayed ICH was on clopidogrel
and two were on both clopidogrel and aspirin. Patients
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with delayed ICH compared with no ICH were older (94
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vs 74 years) with higher injury severity scores (15.7 vs
4.4) and trended towards lower platelet counts (141
vs 216). Patients on aspirin had a higher acute ICH
rate compared with patients on P2Y12 inhibitors (48%
vs 30%, 18% difference, 95% CI 4 to 33; OR 2.18,
95% CI 1.15 to 4.13). No other group comparison had
significant differences in ICH rate.
Conclusions Patients on antiplatelet agents with head
trauma have a high rate of ICH. Routine head CT is
recommended. Patients infrequently developed delayed
ICH. Routine repeat CT imaging does not appear to be
necessary for all patients.
Level of evidence Level III, prognostic.
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Antiplatelet agents are increasingly being used
in the treatment or prevention of cardiovascular
disease.1 2 Patients taking these medications appear
to have an increased risk of traumatic bleeding.3–10
When patients suffer head trauma, an intracranial
hemorrhage (ICH) can occur acutely or delayed. A
number of studies have looked at acute traumatic
ICH in patients taking an antiplatelet agent, with
ICH occurring in approximately 3.6%–67.3% of
patients on antiplatelet therapy and 1.6%–50.5%
of patients not on this therapy.5 The reported risk

of delayed ICH after head injury has varied in the
literature from 0% to 4%.10–16
Several clinical guidelines highlight the risk of
traumatic delayed ICH in patients taking antiplatelet agents.17–19 According to the 2014 National
Institute of Health and Care Excellence guidelines
on head injury, for patients on aspirin or clopidogrel, ‘the reference standard should include CT
head scan and a follow-
up period of sufficient
duration to capture delayed bleeding, for example,
at 7 days and 1 month’.17 Nonetheless, neither
The American College of Surgeons Resources for
Optimal Care of the Injured Patient, sixth edition
released in 2014 nor the Recommendations of the
National Expert Panel on Field Triage published by
the Center for Disease Control and Prevention in
2011 include head trauma or fall in a patient taking
an antiplatelet as a criterion for trauma activation.18 19 In addition, the current American College
of Emergency Physicians’ clinical guidelines do not
specifically list antiplatelet medications as a risk
factor for traumatic ICH.20
With the limited amount of available research
regarding the risk of both acute and delayed ICH,
and the varying methodology and quality of the
literature in patients taking antiplatelet agents, the
objective of our study was to assess the odds of
acute and delayed ICH among head trauma victims
with pre-injury exposure to antiplatelet agents.

METHODS
Study design and setting

This multicenter retrospective investigation was
conducted at two level I trauma centers between
January 1, 2016 and December 31, 2017. The first
site of investigation in central Michigan is a 68-bed
emergency department (ED) with annual census
of 100 000 patients and 676 inpatient beds. The
second site in southeast Florida is a 36-bed ED with
annual census of 70 000 patients and 463 inpatient
beds.

Selection of participants

The trauma registry at each hospital was queried
for inclusion criteria of patients with pre-injury use
of antiplatelet therapy (defined as aspirin, clopidogrel, prasugrel and ticagrelor) seen in the ED by
the trauma team for any head trauma. Exclusion
criteria were age <18 years, no use of antiplatelet
therapy in the last 7 days, prior use of an anticoagulant and those suffering head trauma >24 hours
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prior to ED presentation. All patients meeting these criteria were
included, making up the study sample. Trauma activation at both
hospitals was determined by the prehospital paramedics, who
followed local protocols that mirror the CDC Guidelines for
Field Triage of Injured Patients.19 Antiplatelet use alone did not
warrant trauma activation in the study population. Within the
ED, patients also may have been upgraded to the trauma service
at treating physicians’ discretion.

At both hospitals, the typical trauma workup in the ED consisted
of complete blood count, comprehensive metabolic panel, coagulation studies (prothrombin time, international normalized
ratio (INR) and partial thromboplastin time) and head CT. Some
patients on antiplatelet therapy were admitted for neurological
observation and repeat head CT based on clinician discretion,
although neither hospital had practice management guidelines
dictating such.
A standardized data abstraction form was used that included
the following: age, sex, ethnicity, mechanism of injury, signs and
symptoms, Glasgow Coma Scale (GCS), injury severity score,
initial vital signs, platelet count, coagulation studies, findings
of initial head CT, findings of repeat head CT, performance of
neurosurgical intervention and mortality. Radiographic imaging
was interpreted by board-certified radiologists at both institutions. All data were obtained by chart review from the respective
hospitals’ electronic medical records by one of the coauthors at
each institution.

Outcomes

The primary outcome of the study was the presence of acute or
delayed ICH. An acute ICH is defined as having an acute intracranial bleed on the initial head CT. A delayed ICH is defined as
having an acute finding of intracranial bleeding on the repeat CT
after an initial negative CT. Secondary outcomes included need
for neurosurgical intervention and mortality during the hospitalization. Neurosurgical intervention was defined as the performance, use or placement of an intracranial pressure monitor, an
intraventricular catheter, a subdural drain, a craniotomy/craniectomy or treatment with mannitol or hypertonic saline.

Analysis

Patients were grouped by aspirin alone, P2Y12 alone or aspirin
with P2Y12. Background characteristics of patients were
compared between antiplatelet categories at a significance level
of 0.05 using z-
tests for proportions and t-
tests for means.
Patients in each antiplatelet group were analyzed by primary
outcome (no ICH, acute ICH and delayed ICH). Pearson’s χ2
tests were performed and odds ratios were calculated using Stata
V.16 (StataCorp, College Station, Texas, USA) to compare the
rates of acute and delayed ICH between each of the antiplatelet
groups. The types of ICH (epidural, subdural, subarachnoid and
intraparenchymal) were identified for each antiplatelet category.
The reason for repeat head CT (routine, clinical change or not
repeated) was identified for each primary outcome group. Any
patients with missing data points were excluded from only that
portion of the analysis.

Three hundred twenty-seven patients were included in the analysis: 128 patients on aspirin only, 60 on clopidogrel only, 3 on
ticagrelor only, 0 on prasugrel only, 128 on both aspirin and
2

Patient characteristics by antiplatelet category
Aspirin
(n=128)

P2Y12
(n=63)

Aspirin+P2Y12
(n=136)

Age, mean (SD), years

75 (13)

76 (13)

76 (13)

Female, no. (%)

57 (45%)

27 (43%)

57 (42%)

111 (87%)

54 (86%)

119 (88%)

10 (8%)

6 (10%)

7 (5%)

6 (5%)

3 (5%)

7 (5%)

1 (1%)

0 (0%)

3 (2%)

100 (78%)

56 (89%)

110 (81%)

14 (11%)

1 (2%)*

 Bicycle accident

2 (2%)

2 (3%)

1 (1%)

 Motorcycle accident

3 (2%)

0 (0%)

1 (1%)

 Pedestrian struck by vehicle

5 (4%)

1 (2%)

2 (1%)

 Blunt injury to head (not fall)

3 (2%)

3 (5%)

2 (1%)

1 (1%)

0 (0%)

113 (88%)*

52 (83%)

99 (73%)*

 Loss of consciousness

55 (43%)*

22 (35%)

31 (23%)*

 Headache

Ethnicity, no. (%)
 Caucasian
 African-American

Measurements

RESULTS
Characteristics of study subjects

Table 1

 Hispanic/Latino
 Other
Mechanism of injury, no. (%)
 Fall
 Motor vehicle crash

 Other
Signs of head trauma, no. (%)

19 (14%)*

1 (1%)

Symptoms, no. (%)
63 (49%)

32 (51%)

52 (38%)

 Seizure

1 (1%)

1 (2%)

2 (1%)
10 (7%)

 Nausea

5 (4%)

5 (8%)

 Vomiting

3 (2%)

3 (5%)

5 (4%)

 Dizziness

5 (4%)

5 (8%)

11 (8%)

119 (93%)

61 (97%)

129 (95%)

5 (4%)

2 (3%)

4 (3%)

4 (3%)

0 (0%)

Initial GCS group, no. (%)
 Mild (13–15)
 Moderate (9–12)
 Severe (3–8)
Injury severity score, mean (SD)

10 (9)

3 (2%)

9 (10)

12 (13)

Initial vital signs, mean (SD)
 Systolic blood pressure, mmHg

147 (30)

148 (24)

145 (27)

 Diastolic blood pressure, mmHg

76 (18)

76 (18)

74 (18)

 Heart rate, beats/min

85 (17)*

81 (15)

79 (18)*

 Respiratory rate, breaths/min

19 (4)*

18 (3)

18 (2)*

 Oxygen saturation, %

97 (3)

96 (5)

96 (8)

Platelet count, mean (SD), ×109/L

218 (63)

209 (64)

208 (72)

INR, mean (SD)

1.04 (0.10)

1.05 (0.12)

1.06 (0.11)

*Indicates statistically significant difference between items within the row at
p<0.05 by z-test for proportions and t-test for means.
GCS, Glasgow Coma Scale; INR, international normalized ratio.

clopidogrel, 6 on both aspirin and ticagrelor and 2 on both
aspirin and prasugrel. Overall, the average patient age was
76 years (range 18–97), 43% were female and patients were
predominantly Caucasian (87%). The majority of head injuries
occurred as the result of falls (81%), followed by motor vehicle
collisions (10%). Grouping the patients by antiplatelet classification, 63 patients were on a P2Y12 inhibitor alone and 136
patients were on both aspirin and a P2Y12 inhibitor. Background
characteristics of patients between groups were mostly similar,
although notably, the aspirin+P2Y12 inhibitor group had more
motor vehicle crashes than the P2Y12 group and patients in the
aspirin group had higher rates of signs of head trauma and loss
of consciousness than the aspirin+P2Y12 group (table 1).
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Table 2

Antiplatelet category by head CT result for intracranial hemorrhage (ICH), no. (%; 95% CI)
No ICH

Acute ICH

Delayed ICH

Total

Aspirin

66 (52%; 95% CI 43 to 60)

62 (48%; 95% CI 40 to 57)

0 (0%; 95% CI 0.0 to 2.8)

128

P2Y12

43 (68%; 95% CI 55 to 79)

19 (30%; 95% CI 19 to 43)

1 (1.6%; 95% CI 0.0 to 8.5)

63

Aspirin+P2Y12

82 (60%; 95% CI 52 to 69)

52 (38%; 95% CI 30 to 47)

2 (1.5%; 95% CI 0.2 to 5.2)

136

Total

191 (58%; 95% CI 53 to 64)

133 (41%; 95% CI 35 to 46)

3 (0.9%; 95% CI 0.2 to 2.7)

327

Main results

Overall, 133 patients (40.7%) had an acute ICH and three
patients (0.9%) had a delayed ICH (table 2). Of the patients
with delayed ICH, one was on clopidogrel alone and the other
two were on both clopidogrel and aspirin. When comparing by
antiplatelet groups, patients on aspirin alone had a higher rate
of acute ICH compared with the P2Y12 agents alone (48% vs
30%; 18% difference, 95% CI 4% to 33%; p=0.016; OR 2.18,
95% CI 1.15 to 4.13). There was no significant difference in rate
of delayed ICH when comparing these groups (table 3).
When comparing patients on single antiplatelet therapy
(aspirin or a P2Y12 inhibitor alone) with dual antiplatelet
therapy (aspirin and a P2Y12 inhibitor), there were no significant differences in the rates of acute or delayed ICH (table 3).
Of patients with acute ICH across all antiplatelet groups, most
had either subdural or subarachnoid hemorrhages (table 4). Of
the 191 patients with no initial ICH, 98 had a routine repeat
head CT. No patients with an initial head CT negative for ICH
had repeat imaging due to clinical change. All three patients with
delayed ICH had subdural hemorrhages that were identified by
routine repeat CT imaging (table 5). One patient with acute ICH
did not have indication for repeat CT imaging documented.
Neurosurgical intervention was required for nine patients with
acute ICH. No patients with delayed ICH required intervention.
No study patients died.
Patients with delayed ICH all sustained falls, had signs of head
trauma and were older than 90 years. When compared with no
ICH, patients with delayed ICH were older with mean age of 94
vs 74 years (p=0.009), had a higher injury severity score (15.7 vs
4.4, p<0.001) and trended towards a lower platelet count (141
vs 216, p=0.053). No other variables predicted development of
delayed ICH, including presenting symptoms, GCS, initial vital
signs or INR.

DISCUSSION

In our study of 327 patients taking antiplatelet medications
who sustained blunt head trauma, 40.7% were found to have
an acute ICH. Nine required neurosurgical intervention and
Table 3

none died during the hospitalization. Only three patients
(0.9%) with an initial negative head CT scan were found to
have a delayed ICH on repeat head CT. These delayed ICH
were all found on routine repeat head CT imaging, and not due
to any clinical change. None of these patients required neurosurgical intervention and none died during the hospitalization.
As mounting evidence from the 1960s to the 1980s show low-
dose aspirin to be an effective means of reducing cardiovascular
risk, its use in adults has become widespread. An epidemiological
analysis showed that nearly 30% of all adults aged 40 years or
older in the USA self-report taking low-dose aspirin for primary
or secondary cardiovascular disease (CVD) prevention, and
the prevalence of aspirin use only increases with age.21 The US
Preventive Services Task Force currently recommends low-dose
aspirin use for primary CVD prevention and colorectal cancer.22
Despite the known association between antiplatelet agents and
increased bleeding risk in general, few studies have looked
directly at the odds of acute or delayed traumatic ICH in patients
taking these medications. Among these studies, rates of ICH in
patients on antiplatelet medications presenting with blunt head
trauma ranged from 3.6% to 67.3%.5
Although our study included all adult patients, our patient
population had an average age of 76 years. Our high rate of
ICH may be related to this factor. Prior research has shown that
the geriatric population suffers from a higher rate of acute ICH.
As the brain ages, there is volume loss, making bridging vein
more vulnerable to bleeding along with decreased elasticity.23
The aging US population has led to increased utilization of antiplatelet medications, likely contributing to the increased incidence of bleeds.24
The reported incidence of delayed ICH in the antiplatelet
patient population is 0%–4%.10–16 These studies differed in their
methodology and quality, several were retrospective, others were
from trauma registries and some included patients on vitamin K
antagonists. Our study found that the rate of delayed ICH is
0.9%, on the lower end of the previously reported range. This
suggests that admitting all patients taking antiplatelet medications with blunt head trauma and a negative initial head CT may

Comparison of antiplatelet categories by head CT result for intracranial hemorrhage (ICH)
No ICH

Acute ICH

Delayed ICH

Aspirin vs P2Y12

52% vs 68%
−17%* (95% CI −31 to −2)
P=0.028
OR 0.50 (95% CI 0.26 to 0.93)

48% vs 30%
18% (95% CI 4 to 33)
P=0.016
OR 2.18 (95% CI 1.15 to 4.13)

0% vs 1.6%
−1.6% (95% CI −4.7 to 1.5)
P=0.153

Aspirin vs aspirin+P2Y12

52% vs 60%
−9%* (95% CI −21 to 3)
P=0.153
OR 0.70 (95% CI 0.43 to 1.14)

48% vs 38%
10% (95% CI −2 to 22)
P=0.094
OR 1.52 (95% CI 0.93 to 2.48)

0% vs 1.5%
−1.5% (95% CI −3.5 to 0.6)
P=0.168

P2Y12 vs aspirin+P2Y12

68% vs 60%
8% (95% CI −6 to 22)
P=0.280
OR 1.42 (95% CI 0.75 to 2.66)

30% vs 38%
−8% (95% CI −22 to 6)
P=0.269
OR 0.70 (95% CI 0.37 to 1.32)

1.6% vs 1.5%
0.1% (95% CI −3.5 to 3.8)
P=0.950
OR 1.08 (95% CI 0.10 to 12.14)

*Correct due to rounding.
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Table 4
no. (%)

Acute intracranial hemorrhage type by antiplatelet category,
Aspirin
(n=62)

P2Y12
(n=19)

Aspirin+P2Y12
(n=52)

EDH

0 (0%)

1 (5%)

0 (0%)

SDH

19 (31%)

8 (42%)

31 (60%)

SAH

19 (31%)

4 (21%)

14 (27%)

IPH

6 (10%)

2 (11%)

3 (6%)

SDH+SAH

12 (19%)

3 (16%)

2 (4%)

SDH+IPH

1 (2%)

0 (0%)

0 (0%)

SAH+IPH

3 (5%)

1 (5%)

1 (2%)

SDH+SAH+IPH

2 (3%)

0 (0%)

1 (2%)

EDH, epidural hemorrhage; IPH, intraparenchymal hemorrhage; SAH, subarachnoid
hemorrhage; SDH, subdural hemorrhage.

not be warranted. However, it may be prudent to admit nonagenarians, with higher injury severity scores, and lower platelet
counts.
While the association between anticoagulation and increased
risk of traumatic ICH is well established in the literature, there
are fewer studies quantifying the incidence of traumatic ICH
in patients taking antiplatelet medications. Several studies have
reported no increased risk for bleeding, mortality or neurosurgical interventions with antiplatelet medications.25–28 However,
a meta-analysis with over 20 000 patients showed a pooled OR
of 1.87 (95% CI 1.27 to 2.74) with increased odds of ICH for
patients on all antiplatelet therapy, although not for patients on
aspirin alone.5 This conflicting evidence highlights the need for
more prospective trials on the effects of antiplatelet medications on ICH and the risk to patients. This information would
be valuable as clinicians weigh the risks and benefits of antiplatelet medications, especially in patients who are older with
risk factors for falls.
Our results should be interpreted in the context of several
limitations. First, as patients were enrolled retrospectively into
this study from trauma registries, there likely were patients with
head injuries who presented to the ED and were not seen by
the trauma services. Second, antiplatelet use by patients was
based on documentation in the medical records. Analysis with
platelet function testing was not routinely performed, so it is
unclear if patients were compliant with their antiplatelet medications. Third, the protocol for repeat head CT imaging was not
universally applied. Many patients did not receive a repeat head
CT, limiting the ability to quantify the rate of minor subclinical delayed ICH. Fourth, no follow-up was performed after
the hospitalization. Some patients may have had an acute ICH
and were discharged to hospice, and others may have had a
delayed ICH that occurred after hospital discharge. Although
most delayed cases of ICH occur within the first 24 hours,
some do occur up to 10 days after the initial head injury which
would lead to under reporting of these cases. Finally, this study
Table 5 Head CT result for intracranial hemorrhage (ICH) by reason
for repeat head CT, no. (%)
Routine
No ICH
Acute ICH
Delayed ICH
Total

Clinical change

Not repeated

Total

98 (51%)

0 (0%)

93 (49%)

191

122 (92%)

5 (4%)

5 (4%)

132*

98 (30%)

326

3 (100%)
223 (68%)

0 (0%)
5 (2%)

3

*Missing indication for repeat head CT on one patient with acute ICH.

4

was not designed to have a control group with patients not on
antiplatelets. Therefore, we could only perform comparisons
between antiplatelet groups, rather than examine the effects
of the individual agents on rates of ICH. Additionally, patients
on antiplatelet agents may be more likely to receive a head CT
compared with those who are not, which may lead to an increase
in the ICH rate of limited clinical significance.
The findings of our study suggest that antiplatelet use increases
the odds for the development of acute ICH after head trauma,
with low risk for delayed ICH. Therefore, we recommend that
all patients on antiplatelets with head injury have immediate
head CT imaging. These results are generalizable to patients on
the trauma service with head injury, who are potentially sicker
than the overall emergency department population. However,
even in these patients, we do not recommend routine admission
for observation or repeat head CT imaging on asymptomatic
patients with negative initial head CT imaging. These patients
can safely be discharged home with outpatient follow-up and
strict return precautions.
Our research adds to the previously conflicting evidence,
demonstrating the need for additional investigation in this area.
If future prospective studies confirm the increased rate of ICH
in patients on antiplatelet medications with head injury, trauma
activation guidelines may need to be amended to include these
patients. In addition, identifying risk factors for ICH in patients
taking antiplatelet agents may better inform physicians regarding
the risk-benefit analysis in deciding on antiplatelet therapy.
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